The Exchange has sought clarification from Glenmark Pharmaceuticals with reference to news reported on CNBC TV18 on October 29, 2015 -‘Setback For Glenmark: Sanofi received license Vatelizumab in 2011 & Sanofi not to Pursue Development Of Vatelizumab Molecule.’
The above information is a part of company’s filings submitted to BSE.